Experiment 928161

Details

PropertyValue
Pharmacology
Administration routeSC
OrganismSerratia marcescens (ENTEROBACTERIACEAE)
CitationJAECKLE,KA: MITTELMAN,A: HILL,FH:. (1990). PHASE II TRIAL OF SERRATIA MARCESCENS EXTRACT IN RECURRENT MALIGNANT ASTROCYTOMA.. 8(8)
Amount utilized
Compound isolated
DiseaseIN A PHASE II STUDY, 19 PATIENTS WITH RECURRENT ASTROCYTOMA WERE GIVEN A DOSE WEEKLY FOR 5 WEEKS. AFTER A 2 WEEK REST, A SECOND 5 WEEK COURSE AT THE SAME OR GREATER (3 MG/WK) DOSE WAS GIVEN. 2 PATIENTS SHOWED COMPLETE RESPONSE, 6 SHOWED MINOR RESPONSE AND THE REMAINDER, PROGRESSION. COMMON TOXICITIES WERE TRANSIENT TENDERNESS, INDURATION AND ERYTHEMA AT INJECTION SITES. SYSTEMIC EFFECTS WERE LESS FREQUENT: FEVER, CHILLS, NAUSEA/VOMITING, HEADACHE, ARTHRALGIA AND HYPOTENSION.
Dose amount1.0 MG
Number1
Qualitative resultACTIVE
AnimalHUMAN ADULT
Per unitPERSON
Dose expressionDOSE
ExtractTYPE EXT NOT STATED